Home » Stocks » 10X Genomics

10X Genomics, Inc. (TXG)

Stock Price: $141.15 USD -1.12 (-0.79%)
Updated Oct 26, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 15.00B
Revenue (ttm) 251.31M
Net Income (ttm) -78.05M
Shares Out 78.05M
EPS (ttm) -5.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $141.15
Previous Close $142.27
Change ($) -1.12
Change (%) -0.79%
Day's Open 142.00
Day's Range 139.53 - 144.56
Day's Volume 479,090
52-Week Range 48.78 - 166.31

More Stats

Market Cap 15.00B
Enterprise Value 14.65B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 78.05M
Float 64.54M
EPS (basic) -0.55
EPS (diluted) -5.41
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.88M
Short Ratio 1.82
Short % of Float 2.91%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 59.68
PB Ratio 39.78
Revenue 251.31M
Operating Income -76.48M
Net Income -78.05M
Free Cash Flow -45.92M
Net Cash 344.52M
Net Cash / Share 3.24
Gross Margin 85.18%
Operating Margin -30.43%
Profit Margin -31.10%
FCF Margin -18.27%
ROA -9.13%
ROE -38.39%
ROIC -63.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-7.90% downside)
Current: $141.15
Target: 130.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth68.06%105.83%-
Gross Profit18511860.53
Operating Income-30.57-111-18.38
Net Income-31.25-112-18.76
Shares Outstanding39.0913.3911.59
Earnings Per Share-0.80-8.40-1.62
Operating Cash Flow34.63-76.41-10.70
Capital Expenditures-42.74-6.28-3.76
Free Cash Flow-8.12-82.69-14.46
Cash & Equivalents47670.0947.86
Total Debt29.7229.6810.56
Net Cash / Debt44740.4137.30
Book Value420-220-113
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name 10X Genomics, Inc.
Country United States
Employees 713
CEO Serge Saxonov

Stock Information

Ticker Symbol TXG
Stock Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Unique Identifier NASDAQ: TXG
IPO Date September 12, 2019


10x Genomics, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.